CUB and zona pellucida like domains 1Genealiases: ERG-1 · ERG1 · ITMAP1 · UO-44
Q-omics provides the consensus-scored CUZD1 profile across patient tissues and cancer cell-line models. CUZD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CUZD1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CUZD1 RNA expression shows 16,766 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight COAD, KIRC, and KIRP as cancer lineages where CUZD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CUZD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CUZD1 survival associations across molecular data types. CUZD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CUZD1 RNA expression–survival associations across cancer types. High CUZD1 expression shows unfavorable associations in COAD, KIRC, ACC and LIHC, but favorable associations in UVM and UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CUZD1 RNA expression.
This table summarizes CUZD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CUZD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CUZD1 shows lower tumor expression in UCEC and higher tumor expression in KIRC, THCA, LIHC, HNSC and BLCA. The KIRC box plot shows higher CUZD1 RNA expression in tumor versus normal tissue (log2 FC = +0.419, t-test p < 0.001).
This table shows molecular features associated with CUZD1 in patient tissues and cancer cell lines. In patient samples, CUZD1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CUZD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
